1. Cavazzoni, P. FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. FDA https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (2021).
2. McGinley, L. Two members of an FDA advisory committee quit after approval of controversial Alzheimer’s drug. Washington Post https://www.washingtonpost.com/health/2021/06/09/alzheimers-drug-controversy/ (2021).
3. Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting. Virtual meeting. Friday, November 6, 2020. FDA https://www.fda.gov/media/145691/download (2020).
4. Food and Drug Administration. Aducanumab for the treatment of Alzheimer’s disease: clinical overview of efficacy. FDA https://www.fda.gov/media/143504/download (2020).
5. CNBC. First on CNBC: CNBC transcript: Biogen CEO Michel Vounatsos speaks with CNBC’s “Power Lunch” today. CNBC https://www.cnbc.com/2021/06/07/first-on-cnbc-cnbc-transcript-biogen-ceo-michel-vounatsos-speaks-with-cnbcs-power-lunch-today.html (2021).